ClinicalTrials.gg
TerminatedNCT01907100Updated Mar 18, 2019Results posted

Nintedanib (BIBF 1120) in Mesothelioma

A Phase 2/3 interventional study of Nintedanib and Pemetrexed in Mesothelioma, sponsored by Boehringer Ingelheim. Terminated at 123 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-18.

Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
545
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 188 studies in Mesothelioma with a site in United States — 35 open to participants now, 50 under way, 1 of them phase 3. Mesothelioma · United States.

Enrollment
4th of 164
545 · median 46
Started
2013
with 6 others
Phase 2/3
2 of 188
none open now
Registered
51st of 188
by date

Among the 188 studies in Mesothelioma with a site in United States, this one is the 4th largest by enrollment of the 164 interventional ones that give a count, is one of 7 that started in 2013, is one of 2 in phase 2/3, and was the 51st registered.

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 61 are open to participants now.

Browse Mesothelioma studies →

Open to participants now

35 of the 188 studies in Mesothelioma with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Mesothelioma studies recruiting now, 33 (69%) set no upper age limit and 4 (8%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Mesothelioma with a site in United States, or all of them as a file.
02

Study summary

This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

03

Conditions studied

  • Mesothelioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed malignant pleural mesothelioma (MPM) (Epithelioid or biphasic subtype for Phase II patients; epithelioid subtype only for Phase III patients)
  • of at least 3 months in the opinion of the investigator
  • (ECOG) score of 0 or 1
  • according to modified (Response Evaluation Criteria In Solid Tumours) criteria

Exclusion criteria

Exclusion criteria:

  • Previous systemic chemotherapy for MPM
  • Prior treatment with nintedanib or any other
  • Phase II patients with sarcomatoid subtype MPM or Phase III patients with biphasic or sarcomatoid subtype MPM
  • Patients with symptomatic neuropathy
  • Radiotherapy (except extremities) within 3 months prior to baseline imaging
  • Active (e.g. stable for \< 4 weeks)
  • Radiographic evidence of cavitary or necrotic tumours or local invasion of major blood vessels by MPM
  • Significant cardiovascular diseases
  • Inadequate hematologic, renal, or hepatic function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
545 participants (actual)

Study arms

  • Placebo comparator
    Placebo + pemetrexed/cisplatin

    Placebo controlled arm

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Placebo

  • Experimental
    Nintedanib 200mg + pemetrexed/cisplatin

    Experimental arm

    Drug: Nintedanib · Drug: Cisplatin · Drug: Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    This outcome measure presents progression-free survival. Disease progression was defined according to the modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. For patients with known date of progression (or death): PFS (days) = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS (days, censored) = date of last imaging showing no progression - date randomization + 1 day.

    Time frame: From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the duration of time from randomization to time of death. This is the key secondary endpoint of the trial.

    Time frame: From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)

  2. Objective Response According to Modified RECIST- Investigator Assessment

    Objective response (best overall tumour response of confirmed complete response \[CR\] or confirmed partial response \[PR\]). Complete Response: disappearance of all target lesions Partial Response: at least a 30 % decrease in the total tumour measurement of target lesions, taking as reference the baseline total tumour measurement. Percentage of Patients with confirmed objective response is presented. This endpoint was only evaluated for Phase III part.

    Time frame: Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months

  3. Disease Control According to Modified RECIST- Investigator Assessment

    Disease control (best overall response of confirmed CR or PR, or Stable Disease (SD) that lasted ≥36 days) according to modified RECIST. Percentage of Patients with Disease control is presented. This endpoint was only evaluated for Phase III part.

    Time frame: Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months

07

Results

Posted Mar 18, 2019
Limitations and caveats
In accordance with the specifications in the protocol, the trial was discontinued prematurely after the primary PFS analysis not because of any safety concerns but rather due to failure to meet the efficacy target.

Participant flow

Patients were initially treated with combination therapy consisting of nintedanib or placebo plus standard chemotherapy (pemetrexed/cisplatin), for a maximum of 6 cycles of 21 days duration. After completion of combination therapy, patients who had not progressed continued with nintedanib or placebo monotherapy.

Participant flow — Overall Study
MilestonePlacebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase III
Started4344229229
Treated patients4144228227
Completed148283
Not completed4240147146
Withdrew: Pd based on modified recist criteria31329592
Withdrew: Withdrawal by subject251013
Withdrew: Protocol violation0011
Withdrew: Lost to follow-up0001
Withdrew: Not treated2012
Withdrew: Other than reasons specified10106
Withdrew: Adverse event (ae)632223
Withdrew: Worsening/ae underlying cancer disease0088

Outcome measures

PrimaryProgression-Free Survival (PFS)

This outcome measure presents progression-free survival. Disease progression was defined according to the modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. For patients with known date of progression (or death): PFS (days) = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS (days, censored) = date of last imaging showing no progression - date randomization + 1 day.

Time frame:
From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsPlaceboNintedanib
Phase II5.72 (5.19 to 8.18)9.36 (5.55 to 12.65)
Phase III6.97 (5.42 to 9.00)6.77 (5.36 to 9.07)
Statistical analysis
  • Placebo vs Nintedanib · Proportional hazards mode · p = 0.0174 · Hazard ratio (hr): 0.555 · 95% CI 0.340 to 0.907Hazard ratio, confidence interval and p-value obtained from proportional hazards model stratified by tumour histology (epithelioid vs. biphasic).
  • Placebo vs Nintedanib · Proportional hazards model · p = 0.5430 (one-sided p-value) · Hazard ratio (hr): 1.01 · 95% CI 0.79 to 1.30Hazard ratio, confidence interval and p-value obtained from a non-stratified proportional hazards model.
SecondaryOverall Survival (OS)

Overall survival was defined as the duration of time from randomization to time of death. This is the key secondary endpoint of the trial.

Time frame:
From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsPlaceboNintedanib
Phase II14.46 (10.41 to NA)18.30 (10.91 to NA)
Phase III16.07 (9.66 to 19.29)14.36 (9.13 to 18.69)
Statistical analysis
  • Placebo vs Nintedanib · Proportional hazards mode · p = 0.4132 · Hazard ratio (hr): 0.782 · 95% CI 0.433 to 1.412Hazard ratio, confidence interval and p-value obtained from proportional hazards model stratified by tumour histology (epithelioid vs. biphasic).
  • Placebo vs Nintedanib · Proportional hazards model · p = 0.7306 (one-sided p-value) · Hazard ratio (hr): 1.12 · 95% CI 0.79 to 1.58Hazard ratio, confidence interval and p-value obtained from a non-stratified proportional hazards model.
SecondaryObjective Response According to Modified RECIST- Investigator Assessment

Objective response (best overall tumour response of confirmed complete response \[CR\] or confirmed partial response \[PR\]). Complete Response: disappearance of all target lesions Partial Response: at least a 30 % decrease in the total tumour measurement of target lesions, taking as reference the baseline total tumour measurement. Percentage of Patients with confirmed objective response is presented. This endpoint was only evaluated for Phase III part.

Time frame:
Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months
Reported as:
Number · Percentage of participants
Objective Response According to Modified RECIST- Investigator Assessment
Percentage of participantsPlaceboNintedanib
Objective Response According to Modified RECIST- Investigator Assessment42.8 (36.3 to 49.5)45.0 (38.4 to 51.7)
Statistical analysis
  • Placebo vs Nintedanib · Regression, Logistic · p = 0.3189 (one-sided p-value) · Odds ratio (or): 1.09 · 95% CI 0.76 to 1.58Odds ratio above 1 favours nintedanib.
SecondaryDisease Control According to Modified RECIST- Investigator Assessment

Disease control (best overall response of confirmed CR or PR, or Stable Disease (SD) that lasted ≥36 days) according to modified RECIST. Percentage of Patients with Disease control is presented. This endpoint was only evaluated for Phase III part.

Time frame:
Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months
Reported as:
Number · Percentage of participants
Disease Control According to Modified RECIST- Investigator Assessment
Percentage of participantsPlaceboNintedanib
Disease Control According to Modified RECIST- Investigator Assessment92.6 (88.4 to 95.6)90.8 (86.3 to 94.2)
Statistical analysis
  • Placebo vs Nintedanib · Regression, Logistic · p = 0.7512 (one-sided p-value) · Odds ratio (or): 0.79 · 95% CI 0.40 to 1.55Odds ratio above 1 favours nintedanib.

Adverse events

Collected over SAE & Non SAE: From first dose until 28 days (Phase II) or 30 days (Phase III) after last dose, up to approximately (approx.) 30 months in Phase II and approx. 32 months in Phase III. All-cause mortality: From randomization until end of follow-up, up to approx. 30 months in Phase II and approx. 32 months in Phase III. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo_Phase II25/43 (58.1%)17/41 (41.5%)41/41 (100%)
Nintedanib_Phase II22/44 (50%)16/44 (36.4%)44/44 (100%)
Placebo_Phase III63/229 (27.5%)89/228 (39%)219/228 (96.1%)
Nintedanib_Phase III64/229 (27.9%)99/227 (43.6%)218/227 (96%)
Most frequent serious events
Showing 10 of 168
Most frequent serious events
EventPlacebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase III
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/410/447/22813/227
NeutropeniaBlood and lymphatic system disorders1/413/447/2286/227
DiarrhoeaGastrointestinal disorders0/413/447/2288/227
PyrexiaGeneral disorders2/413/4410/2284/227
Lower respiratory tract infectionInfections and infestations2/410/442/2284/227
DehydrationMetabolism and nutrition disorders2/412/448/2284/227
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/411/442/2280/227
DyspnoeaRespiratory, thoracic and mediastinal disorders2/412/446/2285/227
Pleural effusionRespiratory, thoracic and mediastinal disorders2/410/446/2284/227
AnaemiaBlood and lymphatic system disorders1/412/448/2281/227
Most frequent other events
Showing 10 of 76
Most frequent other events
EventPlacebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase III
NauseaGastrointestinal disorders34/4137/44134/228156/227
DiarrhoeaGastrointestinal disorders15/4129/4447/228118/227
VomitingGastrointestinal disorders20/4124/4466/22896/227
NeutropeniaBlood and lymphatic system disorders9/4122/4482/22883/227
ConstipationGastrointestinal disorders19/4117/4473/22860/227
AnaemiaBlood and lymphatic system disorders9/4116/4494/22876/227
FatigueGeneral disorders15/4118/4462/22860/227
Decreased appetiteMetabolism and nutrition disorders16/4117/4466/22866/227
Alanine aminotransferase increasedInvestigations1/4117/4410/22835/227
CoughRespiratory, thoracic and mediastinal disorders6/4115/4433/22829/227

Baseline characteristics

Randomised Set: This patient set included all randomized patients.

Age, Continuous
Age, Continuous(Years)Placebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase IIITotal
Mean65.9 ± 7.666.4 ± 8.664.3 ± 8.963.6 ± 9.564.3 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase IIITotal
Female8106064142
Male3534169165403
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase IIITotal
Hispanic or Latino————0
Not Hispanic or Latino————0
Unknown or Not Reported————0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo_Phase IINintedanib_Phase IIPlacebo_Phase IIINintedanib_Phase IIITotal
American Indian or Alaska Native00141226
Asian00161430
Native Hawaiian or Other Pacific Islander00000
Black or African American00022
White3838180185441
More than one race00000
Unknown or Not Reported56191646
08

Study locations

123 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Rocky Mountain Cancer Centers
    Littleton, Colorado 80120-4413, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Greenville Health System
    Greenville, South Carolina 29615, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology - McAllen
    McAllen, Texas 78503, United States
  • Texas Oncology-San Antonio Northeast
    San Antonio, Texas 78217, United States
  • Cancer Care Northwest Centers, PS
    Spokane Valley, Washington 99216, United States
  • Sanatorio Güemes
    Ciudad Autónoma de Bs As, C1180AAX, Argentina
  • Instituto Medico Especializado Alexander Fleming
    Ciudad Autónoma de Bs As, C1426ANZ, Argentina
  • Clínica Universitaria Reina Fabiola
    Ciudad de Cordoba, X5004FHP, Argentina
  • Northern Cancer Institute
    St Leonards, New South Wales 2065, Australia
  • Calvary Mater Newcastle Hospital
    Waratah, New South Wales 2298, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Mater Cancer Care Centre
    South Brisbane, Queensland 4101, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Peninsula Haematology & Oncology
    Frankston, Victoria 3199, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Border Onclogy Research
    Wodonga, Victoria 3690, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Perth Oncology
    Perth, Western Australia 6000, Australia
  • LKH Leoben
    Leoben, 8700, Austria
  • AKH - Medical University of Vienna
    Vienna, 1090, Austria
  • Klinikum Wels - Grieskirchen GmbH
    Wels, 4600, Austria
  • Brussels - UNIV Saint-Luc
    Bruxelles, 1200, Belgium
  • Edegem - UNIV UZ Antwerpen
    Edegem, 2650, Belgium
  • UNIV UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • AZ Sint-Maarten
    Mechelen, 2800, Belgium
  • QEII Health Sciences Centre (Dalhousie University)
    Halifax, Nova Scotia B3H 1V7, Canada
  • Health Sciences North
    Sudbury, Ontario P3E 5J1, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • IUCPQ (Laval University)
    Quebec, GLV 4G5, Canada
  • Centro Internacional de Estudios Clínicos - CIEC
    Recoleta, 8420383, Chile
  • Orlandi Oncologia
    Vitacura, 7630372, Chile
  • University Clinic for Pulmonary Diseases
    Zagreb, 10000, Croatia
  • University Hospital Brno
    Brno, 625 00, Czechia
  • University Hospital Olomouc
    Olomouc, 779 00, Czechia
  • Rigshospitalet, København, Onkologisk afdeling
    Købenahvn Ø, 2100, Denmark
  • Clinical Research Center Alexandria
    Alexandria, 21131, Egypt
  • Medical Research Institute
    Alexandria, 21648, Egypt
  • National Cancer Institute, Cairo University
    Cairo, 11796, Egypt
  • Nasser Institute
    Cairo, 12655, Egypt
  • CLI Bordeaux Nord Aquitaine
    Bordeaux, 33000, France
  • HOP Morvan
    Brest, 29609, France
  • HOP Côte de Nacre
    Caen, 14033, France
  • HOP Calmette
    Lille, 59000, France
  • HOP Nord
    Marseille, 13015, France
  • HOP Lyon Sud
    Pierre-Bénite, 69230, France
  • HOP HIA Saint-Anne
    Toulon, 83800, France
  • HOP Larrey
    Toulouse, 31059, France
  • INS Gustave Roussy
    Villejuif, 94805, France
  • Vivantes Netzwerk für Gesundheit GmbH
    Berlin, 12351, Germany
  • Helios Klinikum Emil von Behring
    Berlin, 14165, Germany
  • Klinik Schillerhöhe GmbH
    Gerlingen, 70839, Germany
  • Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
    Großhansdorf, 22927, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Universitätsklinikum des Saarlandes
    Homburg/Saar, 66421, Germany
  • Klinik, Löwenstein
    Löwenstein, 74245, Germany
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Rabin Medical Center Beilinson
    Petach Tikva, 49100, Israel
  • Sourasky Medical Center
    Tel-Aviv, 64239, Israel
  • Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo
    Alessandria, 15121, Italy
  • Centro di riferimento Oncologico
    Aviano (PN), 33081, Italy
  • Humanitas Gavazzeni
    Bergamo, 24125, Italy
  • Istituto Nazionale per la Ricerca sul Cancro
    Genova, 16132, Italy
  • Azienda Sanitaria Ospedale S. Luigi Gonzaga
    Orbassano (TO), 10043, Italy
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • University Hospital of Occupational and Environmental Health
    Fukuoka, Kitakyushu, 807-8556, Japan
  • Hyogo Prefectural Amagasaki General Medical Center
    Hyogo, Amagasaki, 660-8550, Japan
  • Hyogo College of Medicine Hospital
    Hyogo, Nishinomiya, 663-8501, Japan
  • Yokosuka Kyosai Hospital
    Kanagawa , Yokosuka, 238-8558, Japan
  • Japan Labour Health and Safety Organization Okayama Rosai Hospital
    Okayama, Okayama, 702-8055, Japan
  • Kindai University Hospital
    Osaka, OsakaSayama, 589-8511, Japan
  • Otemae Hospital
    Osaka, Osaka, 540-0008, Japan
  • Juntendo University Hospital
    Tokyo, Bunkyo-ku, 113-8431, Japan
  • Centro Oncologico de Chihuahua
    Chihuahua, 31217, Mexico
  • Instituto Nacional de Cancerologia
    Mexico, 14080, Mexico
  • Centro Oncologico Estatal ISSEMYM
    Toluca, 50180, Mexico
  • Medisch Spectrum Twente
    Enschede, 7513 ER, Netherlands
  • Zuyderland Medisch Centrum
    Heerlen, 6419 PC, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CE, Netherlands
  • Oslo Universitetssykehus HF, Radiumhospitalet
    Oslo, N-0310, Norway
  • St. Olavs Hospital, Universitetssykehuset i Trondheim
    Trondheim, N-7006, Norway
  • University Clinical Center, Gdansk
    Gdansk, 80-952, Poland
  • Clin.Hosp.Med.Univ.Marcinkowski in Poznan
    Poznan, 60-569, Poland
  • Greater PL Cent.Pulmo.&Thor.Surg.Eugenia&Janusz Zeyland
    Poznan, 60-569, Poland
  • Onco.Cent. - Instit. of Maria Sklodowskiej-Curie
    Warsaw, 02-781, Poland
  • Centro Hospitalar Lisboa Norte Hospital Pulido Valente
    Lisboa, 1769-001, Portugal
  • Hospital CUF Porto
    Porto, 4100-180, Portugal
  • St.Budg.Heal.Inst."Chelyabinsk Reg.Clin.Cen.Onc&Nucl.Med"
    Chelyabinsk, 454087, Russian Federation
  • St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"
    Kazan, 420029, Russian Federation
  • FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF
    Moscow, 115478, Russian Federation
  • 1stPavlov St.Med.Univ.St.-Petersburg Res.Inst.
    Saint-Petersburg, 197022, Russian Federation
  • FSBI "N.N. Petrov National Medical Research Center of Oncology" of MoH of RF
    Saint-Petersburg, 197758, Russian Federation
  • SBI HC-Rep.Clin.Onc.Disp.MoH.Rep.Bashkortostan
    Ufa, 450054, Russian Federation
  • Wilgers Oncology Centre
    Pretoria, 0041, South Africa
  • Hospital Universitario de Cruces
    Barakaldo (Vizcaya), 48903, Spain

Showing the first 100 of 123 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sorensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15. PubMed 31103412 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2013 to primary completion in Mar 2018, 53 months.

Results were first posted in Mar 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Jul 24, 2013
StartActual
Sep 19, 2013
Primary completionActual
Mar 16, 2018
CompletionActual
Aug 31, 2018
Results first posted
Mar 18, 2019
Last update
Mar 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01907100
Responsible party
Sponsor
First posted
Jul 24, 2013
Start date
Sep 19, 2013
Primary completion
Mar 16, 2018
Completion
Aug 31, 2018
Results posted
Mar 18, 2019
Last update
Mar 18, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion